Type 2 Diabetes

New England CEPAC

The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have diabetes, of whom 95% have the type 2 form.

2019 Intervention of Interest: Oral semaglutide (Novo Nordisk)

2014 Interventions of Interest:

  • Sulfonylureas
  • Insulin
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Glucagon-like peptide-1 (GLP-1) receptor agonists
  • Continuous blood glucose monitoring

For questions, please contact Catherine Koola, Program Manager, at ckoola@icer-review.org.

ASSOCIATED MEETING & MATERIALS

New England CEPAC
November 14, 2019 10am-4pm ET

Brown University
Providence, RI

The New England CEPAC will convene to deliberate on ICER's review of oral semaglutide for the treatment of type 2 diabetes.

Key Dates

Associated Materials

04/11/2019 – 04/29/2019
Open Input Period

05/02/2019

05/02/2019

05/02/2019 – 05/22/2019

05/31/2019

07/08/2019
Research Protocol

07/29/2019
Model Analysis Plan

09/11/2019
Draft Evidence Report

09/11/2019 – 10/08/2019
Public Comment

09/11/2019
Draft Voting Questions

10/31/2019
Revised Voting Questions

11/14/2019
Meeting Agenda

11/14/2019
Evidence Presentation

12/09/2019
Final Evidence Report and Meeting Summary

12/09/2019
Report-at-a-Glance


ASSOCIATED MEETING & MATERIALS

New England CEPAC
October 29, 2014 10:00AM-4:00PM

Brown University, Providence, RI

The New England CEPAC, a core program of the Institute for Clinical and Economic Review (ICER), convened at a public meeting in October 2014 to discuss management options for patients with type 2 diabetes. ICER's report reviewd the comparative clinical effectiveness and value of multiple pharmacological options for second- and third-line treatment in patients with inadequate glycemic control on metformin monotherapy or a combination of metformin and a sulfonylurea, the most widely accepted initial medication choices for type 2 diabetes. The drug classes assessed in the review include: sulfonylureas, insulin, and two relatively new classes of medications, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The New England CEPAC also reviewed the evidence on multiple forms of insulin and methods for insulin delivery, as well as the potential benefits of continuous blood glucose monitoring in this population.

Key Dates

Associated Materials

09/25/2014

09/25/2014

10/29/2014

10/29/2014

10/29/2014

11/06/2014

Public comments received on the Draft Evidence Report.


12/22/2014

12/22/2014
Action Guide For Patients

12/22/2014
Action Guide For Clinicians

12/22/2014
Action Guide For Payers